Severe asthma is heterogeneous in its clinical presentation, underlying pathophysiology, course and response to therapy. Clinical and physiological assessment of severe asthma is often inadequate in predicting underlying disease mechanisms and or response to medications. With the emergence of novel targeted therapies in severe asthma, the need for reproducible, easily measured biomarkers became obvious but only few are currently available for clinical use. These biomarkers along with the clinical presentation of the patient play an important role in identifying phenotypes and endotypes, predicting the clinical course and prognosis and improving the precision therapeutic approach to asthma.

严重哮喘在其临床表现，潜在的病理生理学，病程和对治疗的反应方面是异质的。严重哮喘的临床和生理评估通常不足以预测潜在的疾病机制和/或对药物的反应。随着针对重度哮喘的新型靶向疗法的出现，对可重复，易于测量的生物标志物的需求变得显而易见，但目前只有很少几种可用于临床。这些生物标志物以及患者的临床表现在识别表型和内型，预测临床过程和预后以及改善哮喘的精确治疗方法方面起着重要作用。